Clinical trials: Immunoglobulin
Advanced Cancer, Solid Tumor, Adult
A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies
This is an open-label, non-randomized, Phase 1 study to determine the safety, tolerability, and preliminary efficacy of MCLA-145 in adult patients with advanced metastatic solid tumors or B-cell lymphomas.
- Conditions
- Advanced Cancer, Solid Tumor, Adult, B-cell Lymphoma, Adult
- Trial name
- NCT03922204
- Testing
- MCLA-145, Pembrolizumab (Keytruda)
- Where
- 8 sites in United States, Belgium and 2 more
- Volunteers
- 72 people
- Sponsor
- Merus B.V.
Leukemia, MDS
Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy
Allogeneic hematopoietic stem cell transplantation is the only curative treatment for malignant hematologic diseases. However, immune rejection is a major limitation in its application.
- Conditions
- Leukemia, MDS, Lymphoma
- Trial name
- NCT06895538
- Testing
- Rabbit Anti-Human T-Lymphocyte Immunoglobulin (ATLG)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Peking University First Hospital
HIV Antibodies
Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
Background: The experimental product in this study, N6LS, is a human monoclonal antibody. Antibodies are one way that the human body fights infection. Monoclonal means that all the antibodies in the product are the same.
- Trial name
- VRC 609 (NCT03538626)
- Testing
- VRC-HIVMAB091-00-AB, rHuPH20
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2
Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers
The purpose of this study is to validate the use of a rapid, at home, point-of-care (POC) SARS-CoV-2 IgG antibody test in high risk healthcare workers.
- Trial name
- COVID-Antibody (NCT04334876)
- Testing
- SARS-CoV-2 IgG Antibody Testing Kit
- Where
- United States
- Volunteers
- 571 people
- Sponsor
- Indiana University
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) followed by glofitamab monotherapy treatment regimen (Cohort…
- Trial name
- NCT06806033
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
Synovial Sarcoma
A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma
The purpose of this study is to determine whether immune therapy with anti-CTLA-4 antibody is effective in people with advanced synovial sarcoma.
- Trial name
- NCT00140855
- Testing
- ipilimumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Ludwig Institute for Cancer Research
Rabies
Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies
This is a Phase 2b, double blinded, randomized study of SYN023 compared to HyperRab® (a licensed Rabies immune globulin from human sources, HRIG) for the prevention of rabies as part of post-exposure prophylaxis (PEP).
- Trial name
- ARPEP (NCT03961555)
- Testing
- SYN023, HRIG (HyperRab), Rabies vaccine
- Where
- 14 sites in United States, Philippines
- Volunteers
- 448 people
- Sponsor
- Synermore Biologics Co., Ltd.
Spinal Cord Injuries
TNFα Monoclonal Antibody for Acute Spinal Cord Injury
The purpose of this study is to evaluate the safety and effectiveness of subcutaneous injection of TNFα monoclonal antibody cells for the treatment of traumatic acute spinal cord injury.
- Trial name
- NCT04988425
- Testing
- TNFα Monoclonal Antibody, Methylprednisolone, Saline
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shanghai Changzheng Hospital
Laboratory Assessment SARS-CoV-2 Antibody Levels Before and After Surgery for Patients Requiring Cardiopulmonary Bypass
Quantitative COVID-19 SARS-CoV-2 Antibody Pre and Post Cardiopulmonary Bypass
This study is designed to compare the levels of SARS-CoV-2 antibody prior to cardiopulmonary bypass and after cardiopulmonary bypass (CPB).
- Trial name
- NCT05357885
- Testing
- SARS-CoV-2 Antibody test
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Thomas Jefferson University
Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of EGFR antibody combined with programmed death 1 (PD-1) antibody and chemotherapy in…
- Conditions
- Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma, Metastatic Nasopharyngeal Carcinoma
- Trial name
- NCT06802835
- Testing
- EGFR Antibody, PD-1 antibody, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Sun Yat-sen University
Cholangiocarcinoma, Intrahepatic, PD-L1
PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment
The study aims to evaluate the efficacy and safety of PD-L1 antibody combined with the CTLA-4 antibody in patients with advanced ICC who progressed after standard treatment.
- Conditions
- Cholangiocarcinoma, Intrahepatic, PD-L1, CTLA4
- Trial name
- NCT04634058
- Testing
- PD-L1 antibody combined with CTLA-4 antibody
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Crohn's Disease, Ulcerative Colitis
Assessing the Drug Exposure Risk of Infants Breastfed by Women With Inflammatory Bowel Disease
Breastfeeding is beneficial to both mother and baby. However, many breastfeeding women are affected by long-term health conditions and need to take medications.
- Conditions
- Crohn's Disease, Ulcerative Colitis, Healthy Controls
- Trial name
- NCT03397108
- Testing
- The IBD group was divided into 2 subgroups: with or without anti-TNF antibody use
- Where
- 2 sites in Canada
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- The Hospital for Sick Children
Lymphoma, Non-Hodgkin, Multiple Myeloma
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
The purpose of this study is to evaluate of the study of different CNTO 328 doses and schedules and to see if CNTO 328 has any effect on Non-hodgkin's Lymphoma, Multiple Myeloma or Castleman's disease.
- Conditions
- Lymphoma, Non-Hodgkin, Multiple Myeloma, Giant Lymph Node Hyperplasia
- Trial name
- NCT00412321
- Testing
- CNTO 328
- Where
- 9 sites in United States
- Volunteers
- 67 people
- Sponsor
- Centocor, Inc.
Myelofibrosis, Primary Myelofibrosis
Anti-TGF-beta Therapy in Patients With Myelofibrosis
TGF-β is a cytokine that is found to be upregulated in the bone marrow of patients with myelofibrosis. This cytokine likely plays a dual role in promoting myelofibrosis and myeloproliferation, both of which are the bone marrow…
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Post-essential Thrombocythemia Related Myelofibrosis
- Trial name
- NCT01291784
- Testing
- monoclonal antibody to TGF-beta
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- John Mascarenhas
SARS-Cov2
SARS-CoV2 Antibodies in Pediatric Patients (COVID-19)
Since the beginning of the year, the entire world has been concerned with the novel SARS-CoV2 virus. After the first case descriptions in Wuhan, there has been a rapid increase in the number of cases in Germany as well.
- Trial name
- SARS-CoV2_KIDS (NCT04581148)
- Testing
- Blood test antibodies against SARS-CoV-2
- Where
- Germany
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- University of Erlangen-Nürnberg Medical School
Advanced Solid Tumors
Study of IMC-1121B in Patients With Advanced Solid Tumors
This trial is testing the investigational drug IMC-1121B administered to Japanese participants with advanced solid tumors who have not responded to standard therapy or for whom no standard therapy is available.
- Trial name
- NCT01005355
- Testing
- IMC-1121B
- Where
- Japan
- Volunteers
- 15 people
- Sponsor
- Eli Lilly and Company
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Chemotherapy
Toripalimab-based Neoadjuvant Therapy in LA-HNSCC
The objective of research is to evaluate the efficacy and safety of Toripalimab combined with AP regimen in the treatment of resectable locally advanced head and neck squamous cell carcinoma.122 patients were randomly divided…
- Trial name
- NCT05522985
- Testing
- AP combined with or without Toripalimab
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lyme Disease
Novel Diagnostics for Early Lyme Disease
There are more than 300,000 new cases of Lyme disease every year in the US. Lyme disease is a dangerous bacterial infection transmitted by tick bites and it becomes increasingly severe as the infection progresses.
- Trial name
- NCT03963635
- Testing
- MicroB-plex Lyme Immunoassay
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- MicroB-plex, Inc.
Glomerulonephritis, IGA
Efficacy and Safety of Losartan in Children With Ig A Nephropathy
The investigators hypothesize that using Losartan would help decrease proteinuria in controlling proteinuria in children with immunoglobulin A nephropathy.
- Trial name
- NCT02232776
- Testing
- Losartan
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Seoul National University Hospital
Solid Tumor
A Phase I Study of IBI325 in Patients With Advanced Solid Tumor
The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of IBI325 in patients with advanced solid tumors
- Trial name
- NCT05119998
- Testing
- IBI325 + sintilimab, IBI325
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.